A Look At Edwards Lifesciences (EW) Valuation As Market Sees 17.8% Undervaluation

Simply Wall St.02-23 19:21

AdvertisementWhy Edwards Lifesciences (EW) is on investors’ radar Edwards Lifesciences (EW) has drawn attention after a mixed period for the stock, with gains over the past year and past 3 years set ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613813781?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/411220-main-header/1756234467355","is_english":true,"pubTime":"2026-02-23 19:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613813781","market":"nz","top_or_hot":-1,"title":"A Look At Edwards Lifesciences (EW) Valuation As Market Sees 17.8% Undervaluation","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Edwards Lifesciences (EW) is on investors’ radar Edwards Lifesciences (EW) has drawn attention after a mixed period for the stock, with gains over the past year and past 3 years set ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/a-look-at-edwards-lifesciences-ew-valuation-as-market-sees-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Edwards Lifesciences (EW) Valuation As Market Sees 17.8% Undervaluation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Edwards Lifesciences (EW) Valuation As Market Sees 17.8% Undervaluation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-23 19:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/a-look-at-edwards-lifesciences-ew-valuation-as-market-sees-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Edwards Lifesciences (EW) is on investors’ radar Edwards Lifesciences (EW) has drawn attention after a mixed period for the stock, with gains over the past year and past 3 years set ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/a-look-at-edwards-lifesciences-ew-valuation-as-market-sees-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999001176.USD","symbol_name":"United Global Healthcare Acc USD","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/a-look-at-edwards-lifesciences-ew-valuation-as-market-sees-1","article_id":"2613813781","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/411220-main-header/1756234467355"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/a-look-at-edwards-lifesciences-ew-valuation-as-market-sees-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2613813781","pubTimestamp":1771845665,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Edwards Lifesciences (EW) is on investors’ radar\nEdwards Lifesciences (EW) has drawn attention after a mixed period for the stock, with gains over the past year and past 3 years set against weaker month and year to date returns.\nSee our latest analysis for Edwards Lifesciences.\nRecent trading suggests momentum has cooled a little, with a 1-day share price return of 1.09% and a 7-day gain of 5.15%. These are set against weaker 30-day and year to date share price returns, while 1-year and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999001176.USD":"United Global Healthcare Acc USD","BK4588":"碎股","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","EW":"爱德华兹","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","BK4082":"医疗保健设备","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4504":"桥水持仓","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC"},"translate_title":"市场认为Edwards Lifesciences(EW)估值被低估17.8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EW":1.5},"content_text":"AdvertisementWhy Edwards Lifesciences (EW) is on investors’ radar Edwards Lifesciences (EW) has drawn attention after a mixed period for the stock, with gains over the past year and past 3 years set against weaker month and year to date returns. See our latest analysis for Edwards Lifesciences. Recent trading suggests momentum has cooled a little, with a 1-day share price return of 1.09% and a 7-day gain of 5.15%. These are set against weaker 30-day and year to date share price returns, while 1-year and 3-year total shareholder returns remain positive. If Edwards Lifesciences has you rethinking your watchlist, this could be a good moment to broaden your search with our screener of 27 healthcare AI stocks. With Edwards Lifesciences trading at a discount to one analyst price target and an intrinsic value estimate, yet carrying a low value score of 2, you have to ask: is there hidden upside here, or is future growth already priced in? Most Popular Narrative: 17.8% Undervalued With Edwards Lifesciences closing at $79.78 versus a narrative fair value of $97.11, the most followed view in the market is that the shares are meaningfully underpriced based on long term fundamentals.  The expected approval of the early TAVR indication in the second quarter, along with policy and guideline changes in the U.S. and globally, represents a multiyear growth opportunity that could significantly enhance revenue streams in the future. The planned launch of the transcatheter tricuspid valve EVOQUE in 2024 is anticipated to uniquely position Edwards to gain market share and increase revenues as it becomes the first company to develop and offer this therapy.  Read the complete narrative. Want to understand why this fair value sits well above today’s price? The narrative leans on steady revenue expansion, resilient margins, and a richer future earnings multiple than the sector usually commands. Curious which specific growth rates and profitability assumptions have to line up to make $97.11 add up? Result: Fair Value of $97.11 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you also need to weigh tariff and reimbursement pressures, along with competitive TAVR headwinds in markets like Japan, which could challenge the potential for upside. Find out about the key risks to this Edwards Lifesciences narrative. Another Angle On Valuation So far, the analysis suggests that Edwards Lifesciences appears 17.8% undervalued at a fair value estimate of $97.11. The simple P/E check, however, presents a different perspective, with the current P/E at 43.7x compared with the US Medical Equipment group at 30.5x and a fair ratio of 34.1x. Does that premium indicate quality, or does it point to crowding risk if sentiment cools? See what the numbers say about this price — find out in our valuation breakdown. NYSE:EW P/E Ratio as at Feb 2026Next Steps If this mix of potential upside and clear risks leaves you on the fence, do not wait to stress test the numbers and context yourself. Use 3 key rewards and 3 important warning signs to see how that balance looks in detail. Ready to hunt for more investment ideas? If Edwards Lifesciences has sharpened your focus, do not stop here; use the Simply Wall Street Screener to pressure test fresh ideas before they move.  Target potential value opportunities by reviewing our list of 53 high quality undervalued stocks that pair fundamentals with a price that may still be catching up. Prioritize stability and sleep better at night by scanning 85 resilient stocks with low risk scores that score well on resilience and downside protection. Stay ahead of the crowd by checking a screener containing 23 high quality undiscovered gems that many investors may not be watching yet, but already show solid underlying metrics.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Edwards Lifesciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613813781","isCrawlerRequest":true}